Candida species, belonging to commensal microbial communities in humans, cause
opportunistic infections in individuals with impaired immunity. Pathogens encountered in …

Atypical Candida spp. infections are rising, mostly due to the increasing numbers of
immunocompromised patients. The most common Candida spp. is still Candida albicans; …

Patients with severe COVID-19, such as individuals in intensive care units (ICU), are
exceptionally susceptible to bacterial and fungal infections. The most prevalent fungal …

Candida auris has unprecedently emerged as a multidrug resistant fungal pathogen,
considered a serious global threat due to its potential to cause nosocomial outbreaks and …

Flucytosine is an antifungal agent first licensed in the 1970's. However, its clinical value has
long been overlooked and its availability across the globe is limited. This review highlights …

Abstract The World Health Organization (WHO) in 2022 developed a fungal priority
pathogen list. Candida auris was ultimately ranked as a critical priority pathogen. PubMed …

Candida auris is a multidrug resistant (MDR) fungal pathogen with a crude mortality rate of
30-60%. First identified in 2009, C. auris has been rapidly emerging to become a global risk …

Background New and emerging infectious diseases continue to represent a public health
threat. Emerging infectious disease threats include pathogens increasing in range (eg …

Candida auris, a rapidly emerging multidrug-resistant fungal pathogen, poses a global
health threat, with cases reported in over 47 countries. Conventional detection methods …

Since its first description in 2009, Candida auris has, so far, resulted in large hospital
outbreaks worldwide and is considered an emerging global public health threat …